These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 21194752)

  • 1. B cell immunotherapy in autoimmunity--2010 update.
    Chan AC
    Mol Immunol; 2011 Jun; 48(11):1344-7. PubMed ID: 21194752
    [TBL] [Abstract][Full Text] [Related]  

  • 2. B-cell targeted therapies in human autoimmune diseases: an updated perspective.
    Townsend MJ; Monroe JG; Chan AC
    Immunol Rev; 2010 Sep; 237(1):264-83. PubMed ID: 20727041
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emerging biological drugs: a new therapeutic approach for Systemic Lupus Erythematosus. An update upon efficacy and adverse events.
    Murdaca G; Colombo BM; Puppo F
    Autoimmun Rev; 2011 Nov; 11(1):56-60. PubMed ID: 21835271
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [B cells as key contributors in determining the level of immune responses -B-cell-targeted therapy in patients with autoimmune diseases].
    Kondo S; Akashi T; Katsuta H; Iwakiri R; Anzai K; Nagafuchi S; Niho Y; Harada M
    Fukuoka Igaku Zasshi; 2005 Apr; 96(4):86-92. PubMed ID: 15991605
    [TBL] [Abstract][Full Text] [Related]  

  • 5. B-cell depletion in autoimmune diseases. Advances in autoimmunity.
    Guzman Moreno R
    Autoimmun Rev; 2009 Jun; 8(7):585-90. PubMed ID: 19393204
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD20-depleting therapy in autoimmune diseases: from basic research to the clinic.
    Perosa F; Prete M; Racanelli V; Dammacco F
    J Intern Med; 2010 Mar; 267(3):260-77. PubMed ID: 20201920
    [TBL] [Abstract][Full Text] [Related]  

  • 7. B cell-directed therapies for autoimmune disease and correlates of disease response and relapse.
    Levesque MC; St Clair EW
    J Allergy Clin Immunol; 2008 Jan; 121(1):13-21; quiz 22-3. PubMed ID: 18206502
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Rationale and clinical evidence for the use of rituximab in glomerular diseases].
    Mani LY; Vogt B; Burnier M; Golshayan D
    Rev Med Suisse; 2011 Apr; 7(290):819-24. PubMed ID: 21595313
    [TBL] [Abstract][Full Text] [Related]  

  • 9. B lymphocytes in systemic lupus erythematosus: lessons from therapy targeting B cells.
    Looney RJ; Anolik J; Sanz I
    Lupus; 2004; 13(5):381-90. PubMed ID: 15230297
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of rituximab in patients with systemic lupus erythematosus: an update.
    García-Carrasco M; Jiménez-Hernández M; Escárcega RO; Mendoza-Pinto C; Galarza-Maldonado C; Sandoval-Cruz M; Zamudio-Huerta L; López-Colombo A; Cervera R
    Autoimmun Rev; 2009 Feb; 8(4):343-8. PubMed ID: 19036350
    [TBL] [Abstract][Full Text] [Related]  

  • 11. B cell-targeted therapy with rituximab and autoimmune neuromuscular disorders.
    Stübgen JP
    J Neuroimmunol; 2008 Nov; 204(1-2):1-12. PubMed ID: 18783837
    [TBL] [Abstract][Full Text] [Related]  

  • 12. B-cell-depleting therapy in systemic lupus erythematosus.
    Ramos-Casals M; Sanz I; Bosch X; Stone JH; Khamashta MA
    Am J Med; 2012 Apr; 125(4):327-36. PubMed ID: 22444096
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Recombinant proteins or monoclonal antibodies: comparative properties and interest in systemic lupus erythematosus].
    Terrier B; Mouthon L
    Med Sci (Paris); 2013 Jan; 29(1):65-73. PubMed ID: 23351696
    [TBL] [Abstract][Full Text] [Related]  

  • 14. B cell-targeted therapy in autoimmune disease: rationale, mechanisms, and clinical application.
    Mease PJ
    J Rheumatol; 2008 Jul; 35(7):1245-55. PubMed ID: 18609733
    [TBL] [Abstract][Full Text] [Related]  

  • 15. B cell depletion therapy in systemic lupus erythematosus.
    Anolik J; Sanz I; Looney RJ
    Curr Rheumatol Rep; 2003 Oct; 5(5):350-6. PubMed ID: 12967516
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of autoimmune nephritis in genetically asplenic and splenectomized BAFF transgenic mice.
    Fletcher CA; Groom JR; Woehl B; Leung H; Mackay C; Mackay F
    J Autoimmun; 2011 Mar; 36(2):125-34. PubMed ID: 21216131
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Crossroads of B cell activation in autoimmunity: rationale of targeting B cells.
    Dörner T
    J Rheumatol Suppl; 2006 May; 77():3-11. PubMed ID: 16652439
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of SLE with anti-CD20 monoclonal antibody.
    Looney RJ; Anolik J; Sanz I
    Curr Dir Autoimmun; 2005; 8():193-205. PubMed ID: 15564722
    [TBL] [Abstract][Full Text] [Related]  

  • 19. B cell-directed therapies in type 1 diabetes.
    Mariño E; Silveira PA; Stolp J; Grey ST
    Trends Immunol; 2011 Jun; 32(6):287-94. PubMed ID: 21531625
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New therapies for systemic lupus erythematosus: cellular targets.
    Looney RJ; Anolik J; Sanz I
    Rheum Dis Clin North Am; 2006 Feb; 32(1):201-15, xi. PubMed ID: 16504831
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.